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The low cost, high versatility, and reliable produc-
tion of bacterially produced recombinant antibody 
fragments speeds up the development of tumor-
targeting agents. High-quality recombinant anti-
melanoma antibodies are much sought after in the 
scientific community. We cloned the murine anti-
body 225.28S, currently used in radioimmunoimag-
ing of human melanoma lesions, in single-chain Fv 
configuration (scFv) for soluble expression in bacte-
ria. The recombinant antibody fragment conserved 
the binding specificity of the parental antibody. In 
order to arm the scFv(225.28S) with biologically use-
ful effector functions, we developed vectors for sol-
uble expression ofscFv(225.28S) in bacteria that allow 
both covalent and noncovalent chemical antibody 
modification at positions that do not interfere with 
antigen binding. An expression vector was developed 
that appends a cysteine residue at the C-terminal 
A nalysis of human tumors with monoclonal antibodies (MAbs) has identified a variety of tumor-associated antigens with vario us degrees of tumor specificity. T he restricted tissue di stribution of some of these antigens has relcindl ed interest in the application of 
radio imaging techniques for diagnostic purposes and possible ther-
apeutic treatme nts. 
MA bs to tumor- associated antigens expressed by m elanoma, 
glioma, and carcinomas of breas t, gastrointestinal tract, and ovary 
have already been successfully used to radioimage (McKeam, 1993) 
and, in som e cases, to treat lesions in patients with the correspond-
ing tumors (e.g., Goldenberg, 1993 ; Riva et aI, 1994). 
Manuscript received October 12, 1995; rev ised March 19, 1996; accepted 
fo r publi ca tion April 15, 1996 . 
Reprint requests to: Dario N eri , Cambridge Centre for Protein Engineer-
ing, MItC Centre, I-li ll s Road, Cambridge CB2 2QH , U .K. 
Abbrevia tions: CAL, calmodulin ; Fab, antibody fragment; HMW-MAA, 
high-molecular weight melanoma-associated antigen; MAA, melanoma-
associated antigen; MAb, monoclonal antibody; protein LG, immunoglob-
ulin binding protein; SAD, second antibody binding; scFv, single- chain Fv . 
" Current address: Development Department, I.R.I. S.-BIOCINE, Via 
Fiorentina, 1, 53100 Siena, Italy. 
extremity of the recombinant antibody, thus allow-
ing reaction with thiol-specific reagents, including 
99IUTc labeling, at a position that does not interfere 
with antigen binding. The scFv(225.28S) was also 
successfully expressed with a casein kinase II sub-
strate tag that enables efficient and stable 32p label-
ing. For nOl1covalent antibody modification, we de-
veloped an expression vector that appends the human 
calmodulin gene at the C-terminal extremity of 
scFv(225.28S). The calmodulin domain is poorly hn-
munogenic and can be targeted with chemically 
modified high-affinity calmodulin ligands. The re-
combinant anti-human melanoma antibodies de-
scribed in this article should prove useful "building 
blocks" for the development of anti-melanoma diag_ 
nostic and therapeutic strategies. Key words: scFvl 
recombillant alltibodiesllllllllan melmtomalantibodJl jltllctio,,-
alizatioll, ] In.,est Dermatol 107:164-170, 1996 
T he high-affinity murine JgG2a monoclonal antibody (MAb) 
225.28S (Nata li e( aI, 1984) is specific for a high-m olecular weig h t 
m elanoma-associated antigen (HMW-MAA). The antigen shows 
several biologic features of clinical relevance, namely, its expression 
by at least 90% of m elanoma lesions (Natali e/ aI, 1984), the fact that 
it is less heterogeneous in its expression than other types of MAAs 
investigated (Natali e( aI, 1983), that it displays a highly-restric ted 
normal tissue distribution (Natali c( aI, 1984), and that it is present 
only in minute amounts in serum of patients with advanced disease 
(Giacomini c ( aI, 1984). 
Previous multicenter studies (Buraggi e( aI, 1985; Siccardi et aI , 
1986, 1987) have shown that the labeled anti-melanoma antibody 
225 .28S localizes m etasta tic melanoma les ions in patients . To 
improve imaging results and to explore possible therapeutic appli-
cation s, different radionuclide labels and imagin g approaches, fr0111 
direct radio labeling to multistep teclmiques based on the avidil1-
biotin system , have been developed (Paganelli c ( aI, 1991) . Because 
225.28S MAb-based radiopharmaceuticals have been shown to be 
useful in the managem en t of melanoma patients (Siccardi et aI, 
1987), there is interest in the production of a recombinant mole-
cule, for example, a recombinant singl e-chain Fv fragment (scFv; 
Bird e ( aI, 1988; Huston e( aI, 1988), wh.ich may find therapeutic 
applicatio ns and which the scientific community may use as a 
0022-202X/96/S10. 50 • Copyright © 1996 by The Society for In vestigative Dermatology, Inc. 
164 
VOL. 107 , N O, 2 AUG UST 1996 
" targeting unit" for m odular m elanoma-targeting approaches. W e 
here report the clonin g and ch aracteriza tion of the 225. 28S anti-
body in different recombinant form ats in tenns of performance and 
functional affinity for its biologic target. 
MATER.lALS AND METH O DS 
Antibodies and Cell LilIes T hc generation of MAb 225,28S to a high 
m olecular wcight melanoma-associated antigen (Nata.!j el ai, 1984), MA b 
9EI0 (Munro and Pelham, 1986), and scFv(D1. 3) (McCaffe rty el ai , 1990) 
h as been dcscribed previo usly. T he anti-225. 28S idiotypic antibody MF-l1 
was a gift from Dr. Soldano Ferrone (New York Medical College, Valhalla, 
N Y) . T he anti-ca lmodulill (CAL) human antibody fragmcnt (Fab) 
D N1 69/F3 (Neri '" ai, 1995a) was isolated by D .N . as described (Griffiths ef 
ai, 1994) . Purified 225.28S M Ab. F(ab)2' and Fab fragmcnts were obtained 
as dcscribed (Mariani el al. J 991) . 
T he continuo us melanoma cc ll linc COLO-38 was maintained in 
P. G. N .'s laboratory in RPMI 640 medium supplemented wi th 10% heat-
inactivated fe tal calf se rum (GIBCO BRL, Gaj thersburg, MD) and 2 mM 
glutamjne. T he carcinocmbryonic antigen-expressing HT 29 ce ll line was 
o btained from the Am erican Type C ulture Collection (Bethesda, MD). 
Cloning, Stability, and FUllctionalization of scFv(225.28S 
C lollillg of225.285 ill scFII C OIifrglll'nlioll The rescue o f the antibody VH an d 
VL genes fo llowed the strategy described by T . P. Bonnen [PhD Thesis, 
U niversity of C ambridge (UK) , 1994), a modifi cation of the method of 
C lackson ef al (1 991) in which VH and Vk domains are cloned sequen tially 
in pHEN1-based vec tors (Hoogenboom el ai, 1991) . Positivc clones were 
id entifi ed by an alysis of bacterial supcrnatants expressing the scFv fragment 
(M arks et ai, 1991) fo r binding to the anti-idiotypic antibod). MF- l1 
(Kusama el ai, 1989) on a BIAcore biosensor machine (Pharmacia, Piscat-
away, NJ; J onsson el ai, 1991) . A clone positive in BIAcorc was selccted and 
sequenced acco rdillg to st31ldard procedures. Its nuclco tide sequence and 
the amino acid sequence havc been deposited at the EMBL Sequence 
D atabase (accession number X9 5707). T hesc sequences coincide with those 
of the parental antibody. 
Expressioll Veclors scFv(225.28S) was subcloned in the Sfil I Noll cloning 
sites of vec tors pDN23, pDN227, and pDN15 2, yjelding clones pDN49, 
pD N 284, 31ld pDN206, respectively. pDN23 is a derivati ve of pl-lE N1 
(H oogcnboom el ai, 1991), which does not contain the phage gene Tn 31ld in 
w hich the sequence between the NOll and the EcoR.l sites (lI11dedilled) has been 
replaced by the sequence: GCGGCCGCAGGCGGTTCTTCCGGCTCCT-
G TGAACAAAAACTCATCTCAGAAGAGGATCTGAATTAAT AAGAA-
TTC. Cloning of a recombinant antibody in the SfillNo fl sites of pD N 23 
results in a C-tenninal extremity of the molecule containing a heptapeptide 
sequence GGSSGSC, followed by the myc tag. W e refer to this fonna t as 
scFv-Cys-myc. pDN227 (Neri cl ai, 1996a) appends the sequence DDDSD-
DDDYKDDDDK at the C-ternlinal extremjty of the scFv fragment, where the 
boldface serine residue can be phosphorylated by casein kinase n (Marin 01 ai, 
1986) , and the IIlIdedilled sequence corresponds to the FLAG tag (Hopp el ai, 
1988). W e refer to tlus fonnat as scFv-P-FLAG. pDN152 (Neri ef ai, 1995a) 
appends CAL, a small protein of 148 amino acids, to the C-ternlinal extrenuty 
of the antibody . W e refer to tlus fomlat as scFv-CAL. 
Expressioll alld P"'!ficalioll of SCF,,(225, 28S) In a typical protocol, the clone 
ofulterest (pDN49/ TGI , pDN284/ T Gl, or pDN206/TG1) was inoculated 
in to 1 liter 2xTY medium containing 0.1 % glucose and 100 mg of ampicillin 
per liter and grown at 37°C until O D 6 {10 = O. S. IsopropylthiogaJacto pyr-
anoside was then added to a final concentra tion o f 1 mM, and growth was 
continued with shaking at 20°C for 16 - 20 h . The suspension was til en 
centrifuged and the supernatant filtered and concentrated to 1 I I 0 of the 
o n gina.! volume using a Filtron Minjsette filtration device (Filtron TeclUlol-
ogy Corp., Northborough, MA), using benzamidille (10 mg per liter) and 
soybean trypsin illiubitor (10 mg per li ter) as protease inhibi tors. 
The scFv(22 5. 28S)-Cys-myc was purified fro m tllis solution by chroma-
tography on either a column prepared w i til the anti-myc tag antibody 9El 0 
(Marks el. ai , 1991) o r on a column prepared with LG protein (Kihlberg el ai, 
1992; Vola el ai, 1994) as described . The scFv(225.28S)-P-FLAG was 
affinjty purified on an anti-FLAG resin (M2 resin , Kodak IBI) according to 
the manufacturer' s instructions. T he scFv(225. 28S)-CAL was purified 
sequentially by affinity chromatography on N- (6-aminohexyl)-5-chloro-l-
naphthalenesu.!fonamide-agarose (Sigma C hemical Co. , St. Loujs, MO) and 
by 31uon exchange chromatography on a Mono-Q column on a Ph~nnacia 
FPLC system as described (Neri et ai , 1995a) . In all three cases, the yjelds 
were on tbe order of 1-10 mg per lite r of cultu.re . C lones expressing 
scFv(225 .28S) tend to lose expression competence ifkept on agar plates 31ld 
are be tter stored as glycerol cultures or as plasnuds. 
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FIIIICfiollaliz arioll of scFII(225.285) Purified scFv(225.28S)-Cys-myc was 
functionalized with iodoacetamido-LC-biorill (Pierce , R ockfo rd , IL) or 
with iodoace t31llido-fluorescein (Molecular Probes , Eugene, OR) using 
similar protocols. The antibody (1 mg/ml) was fus t redu ced w ith 1 m M 
T ris(2-carboxyethyl)phosphine hydrochlo ride (Molecular Pro bes) in PBS 
(phosphate-buffe red saline; 50 mM phosphate buffe r, pH 7.4, 100 mM 
N aCI) for 30 min on icc, and iodoacetamido flu orescein o r LC- biotin (2 
mM stock in dimethyl fo rmamide) was added to the antibody solution in the 
volume ratio 1 (reagent solution): 10 (an tibody solu tion). T he reaction was 
allowed to proceed for 3 h on ice in the dark and was then quenched with 
10 mM dithio tllreito l. T he residual functionalization reagent was fi na.!1y 
removed by gel fi ltration on PD-I 0 desalting co lumns (Pharmacia) eq uili-
brated with PBS. 
Fluorescein labeling was checked by sodium dodecyl sulfate-polyacryl-
amide gel electropho resis on H omogeneous 20% Phast gels (Pharmacia) 311d 
imaged wi th the cooled CCD-cam era gel imaging system LUANA (N eri Of 
ai, 1996b) . Antibody bio tinylation was checked by radioimmunoassay after 
coa ting plates with the anti-idiotype antibody MF-l1 (5 J.Lg pcr ml) (Kusam a 
el ai, 1989), and using ' 2s l_labeled streptavidin as detection reagent. 
ScFv(225.28S)-P-FLAG was phosphorylated with [y_"2p)ATP an d casein 
kinase II as descl; bed (N eri cl ai, 1996a). 
Serologic Activity 
BIAco fe Allall'sis scFv(225.28S) bin ding to its anti- idiotypic an tibody 
MF-l1 w as assayed by surface plasmon resonance technjques using a 
BIAcore machine (Phanllacia) Oonsson er ai, 199 1. ). Seven tllO usand 
resonance units o f purified MF-l1 (Kusama el ai, 1989) were immobilized 
on a BlAcore l11icrosensor clup at pH 4.8 using standard NI-IS-EDC 
chenustry. Binding was clearly o bse rved witll scFv(225.28S)- tag (tag = 
Cys-myc, P-FLAG, or C AL) supernatants and puri fied p reparations, bu t not 
with supernatants containing scFv(D 1.3) and scFv (HyHEL-l 0) antily-
sozym e antibodies (Neri ef ai, 1995b) used as negative controls. 
~ffi"il)' Comlalll Dete,.", illalilm Affini ty constan ts fo r ti, e 225.28S IgG 
molecule and for the F(ab)2' Fab, and scFv-Cys-myc fragments toward the 
high molecular weight melanoma-associated an tigen (HMW -M AA) were 
determined on COLO -38 cells witll the Second Antibody Binding (SAB) 
metilOd (Mariani el ai, 1987) . A microtiter plate was blocked with PBS-
gelatin 1 % (200 J.LI per well) for 3 h at 37°C. COL038 melanoma ceUs (2.5 
X 105) washed in PBS were then added to each well in a to tal volume of200 
J.L1. T he plate was cen trifuged (3 mjn , 1500 rpm) and the supernatant 
removed . Antibodies at differen t concentration s were added to differen t 
wells and incuba ted for 2 h at room tempera ture. T he plate was washed five 
times with PBS/O.O l % Tween-20, after wluch 100 J.Ll of ' 2sI_l abeled protein 
LG (1 50,000 cpm per well ; specific activity 10-15 J.LC i per J.Lg) were added 
to cach well and incubated ovenught at 4°C. T he plate was finally washed 
fi ve rilnes witll PBS/0.01 % T ween , a"d the well s were cut and counted in 
a gamma counter. T he counts ob tained were elaborated with the SAB 
program (Mariani el ai, 1. 987) . SAB curves w ere built using the four-
param eter logisti c function, and the affinity cons tan t was evaluated as the 
reciproca l of the antibody concentration giving 50% satura tion of binding. 
1Il1'llIlIIohisloche",iw l A nalysis Surgical biopsies of norm a.! tissues and mela-
noeytic lesions were obtained from the Surgical Pathology section of tI, C 
R egina Elena Can cer Institute . T issue samples wcre snap-frozen in liquid 
lutrogen . From each specimen 4-J.L111 cryos tat sections were ob tained an d 
ti.xed in absolute acetone for 1. 0 min. Sections were eitller immediately used 
in immunolustochemica.! assays or kept frozen at -20°C (with no loss of 
serologic activity). Fixed sections stain ed with l 'i!, toluidine blue were used 
to evaluate the lustologic features of d,e lesions. T he indirect immul1oper-
oxidase stain, aimed at evaluarillg tile ability o f scFv an tibody fragments to 
recognize the HMW-MAA expressed ill lIillO, was perfo rmed as fo llows. 
Sections were incubated sequentia.!ly fo r 1 h w ith scFv(225 .28S)-Cys-myc 
(1 0 J.Lg per ml) , MAb 9E10 to c-myc peptide (10 J.Lg per 1111), 31ld 
bio tin-labeled anti-mouse immulloglobuwl 31ltiserum . After til e last incu-
bation, the immune reaction was detected with a commercially available 
avidin-bio ril, system (Vectastain Elite, Burlingam e, CAl . T he enzymatic 
activi ty was developed using 3-amino-9-etllylcarbazole as cllromogenic 
substrate for 8 min. Slides w ere cowuerstained wi tll Mayer's hematoxylin . 
Slides on which the incubation \vitll the scFv(225.28S) was onutted were 
used as negative contro.\. For comparison. the immwlOlustochenu ca.! reac-
tivity o f MAb 225 .28S was evaluated in para.!l el on the same surgica.! 
biopsies by the sam e method . 
]mllll'llOhistochemisll}, ~fscFII(225,285) Bil,dill<~ 10 COL038 Cells COLO-38 
cell s. expressing the HMW-MAA on their membr31le, and HT29 (negative 
control; not shown) were grown on microscope glass cover slips in RPM] 
medjum + 10% fetal bovine serum . W hen tile cells had grown almost to 
confluence, the cover slips were washed witll PBS and incubated with (i) 
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Figure 1. T h e schematic structure of scFv(22S.28S) w ith conve-
nient s ites for antibody luodification. a) Schematic representation of 
the VH and V L domaim of the 225 .21>S anti body assembled in scFv 
configuratio n. T he seq uences of the three tags arc in Mnleria /s alld Melh"ds. 
h) Scheme of the express ion vecto rs fo r scFv(225 .28S); rbs, ribosome 
binding site; PeiB, leader sequence; VH and Vk, immunoglo bulin variable 
domains ofsc l=v(225.28S); (GGGGS).l' hyd ro philic I S-mer linker; stop, two 
stop codo ns, R.c le va n t restri c tions sites and an lino acid sequences arc 
indicated. c) Nucleotide and ami no ac id sequence of the VH and Vk genes 
of scFv(225.28S). 
scFv-CA L (10 ILg pCI' 1111 ; antibody: 225.28S or H yHEL-I O (Neri cl ai, 
1995a) as negative control) . anti-CAL human Fab D N169 / F3 (Neri el (//, 
1995a), and an ti-hulll an Ck-FITC (Sigma), or (ii) scFv-P-FLAG (10 ILg per 
ml ; antibody: 225.28S o r H yH EL-IO (Neri cl (/ /. 1996a) as negative control), 
an ti-FLAG M2 'lI1 tibody (Kodak 1131) , and FITC-Iabeled rab bit anti-mouse 
IgG (Sigma), o r (iii) IgG (10 ILg per ml; 225.28S or 9E IO as negative 
contro l), FITC-Iabe led rabbit anti-mouse IgG (Sigma), and analyzed with 
an MRC-600 confocal laser microscope. Images were acqui red and printed 
under ide nti cal conditions. 
T H E JOUIlNAL OF INVESTIGATIVE D ERM ATOLOGY 
2 1.6 
21.2 / 20.8 20.4 
Relative 20.0 
response 19.6 a b (kRU) 19.2 
18.8 
18.4 
18.0 '---
17.6 
17.2 
16.8 
500 1000 1500 
Time (s) 
Figure 2 . The binding of scFv(22S .28S) to its anti-idiotypic anti-
body MF-l1 confirms the su ccessful conversion of IgG(22S .28S) in 
scFv format . BIAcorc analysis of sCl'v (225.28S) bind ing to a microsensor 
chip coa ted with 7000 resolla nce uni ts of the anti-idiotypic antibody MF-l 1 
(Kusama el ai , ·1989). (/ , The scnsogram shows the b inding of the recombi-
nant antibody sUl'cl'I1atant to MF-ll , fo llowed by a Aat (i.e. , very slow) 
di ssociation profile with signal clearly above the base line. T he ve rtical 
increase and decrease in signal at the beginning and at the end o f antibody 
injection are due to refi'active index changes . T he sha pe of the association 
curve ind icates that the surf.1ce is not saturated . b, A noncorrela ted 
anti-lysozy me antibody supernatant does not bind; the baseline remains at 
the salll e leve l before and after injection. 
KESULTS 
ScFv(225.28S) Can Be Expressed, Purified, and Modified 
with Different Tags Starting from the 225.28S hybridoma, we 
cloned the sc Fv(225.28S) w ith the conventional (Gly-Gl y- Gly-Gly-
Ser)3 15-mer linker as described (C lackson el nl, 1991 ). T he VH 
and VL gene sequ ences, reported in Fig le, coincide with those 
obta in ed fi·o l11 the 225.28S hybridoma. T he co lonies obtained were 
gro wn for soluble antibody expression , and positive clones were 
identified by surface plasmon resonan ce anal ys is with a BIAcore 
machine (Pharm acia), usin g the anti -225 .S28 anti-idiotypic anti-
body MF-11 (Kusa ma el nl, 1989) as probe (Fig 2) . Specifi c binding 
42.7 
30.0 
17.2 
12.3 
1 2 
Figure 3 . ScFv(225.28S) can be affinity-purified to homogeneity . 
Polyacrylamide gel electrophoresis anal ysis of9E'J O-puri fied scFv(225.28S)-
CYS-lll YC. M o lcculaT weigh t nl arkc rs nre indicated, 
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Figure 4. Diflcrent formats of scFv(225.28S) can be modified co-
valently or nOllcovalently. a, 20% SDS-Phase Ge l (Pharmacia) of 
scFv(225.28S)- Cys(Huorcscein) -myc. imaged with the cooled-CCD cam-
era-based Huorescent ge l image r LUANA (Kinetic Imaging. Liverpool, 
UK" and D igita l Pixel, Brigheon. UK) . Lalle J. USA-FITC (60 kDa) + 
Soybean Trypsin Inhibi to r- FITC (20 kDa); lallc 2, scFv(225.28S)-Cys(Huo-
resce in)-myc; Inlle 3, scFv(D1.3)- Cys(Fluo rescein)-myc . Ii, Mo lecular Dy-
namics (Sunn yva le, CAl Phosphorlmager au toradiogram of a 20% SDS-
Phast Gel (Pharmacia). Lalle 1, .12P- labc led scFv(H yHEL- 1 O)-P- FLAG; Inlle 
2, J2P_labelcd scFv(225.28S). c, 20'10, Native Phase Gel (Pharmacia) of 
scFv(225.28S)-CAL in the complex with I p.M ca lmodulin- binding TAG3-
Huoresccin, imaged with LUANA. Experimental conditio ns as described 
(Neri el al. 1995a). T he blark balld at the top of the gel co rresponds to the 
interf., ce between stacking and running gel in Phannacia Phast gels. 
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Table I. Bivalent 225.285 Antibody Formats Exhibit 
High Apparent Affinity Toward COLO-38 Cells 
An tibody format 
IgG 
F(ab)2 
Fab 
scFv- c)'s 
1.0 X lO ,n 
1.0 X 10'0 
7.7 X 10" 
4.8 X 10" 
.. Apparent aflinity co nstants. displayin g :nrirliry effects :1S n fUllction of antibody 
va "! Jl l:)' (Crolhers and Metzger, 1972). were. measured with a SAB protocol (Mariani 
<I til, 1987) . 
is observed with scFv(225.28S), but not with the anti-lysozyme 
scFv(HyHEL-l0) (Nel; el ai, 1995b) . 
For facile chemical modification of our anti-melanoma antibod-
ies, we cloned the scFv(225.28S) gene into suitable expression 
vectors, yielding vectors pDN49, pDN284, a.nd pDN206, which 
append different tags at th e C-terminal extrem.ity (Fig 1 and 
Ma terials alld /IIfethods). pDN49 appends a cystein e residue followed 
by a peptide tag (myc-tag; Munro and Pelham, 1986) useful for 
protein purification and detection . T he thiol group of the cysteine 
residue allows si te- specific and stoichiometrically defined function-
alization of the recombina.nt antibody with thiol-specific reagents at 
a position that does not interfere with antigen binding (Cumber et 
ai, 1992; Neri et ai, 1995b) and does not result in loss ofimmuno-
reactivity (for a review, N et; el ai, 1995c) . pDN284 appends to the 
F igure 5 . ScFv(225.28S) binds specifically to melanoma cells. Confocal laser microscope analysis of antibody binding [0 COLO-38 m elanoma cells; 
a, scFv(225.28S)-P-FLAG ; (), IgG(225.28S); c, scFv(H yHEL-10)-P-FLAG; d, IgG (9E10). 
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c d 
e f 
Figure 6. ScFv(225.28S) and MAb(225.28S) stain melanocytic le-
sions, but not normal tissues. Kcactiv ity was revealed by avidin-biotin 
indirect immunopcroxidasc sta ining on 4-fLm acetone- fix cd cryostat scc-
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Table II. Mclanocytic Lesions Are Stained Specifically 
by Both scFv(225.28S) and IgG(225 .28S) 
Normal tissucs 
C uti s 
Liver 
Thyroid 
Parotid 
Colon-rectum 
Kidncy 
Vascular wa ll 
Mclanocytic lesions 
Nevoce Liul ar nevi 
Prinlary nlcianOll1aS 
Metastatic In c l a nOlllt1S 
scFv 
Basal keratinoc),tcs 
+ 
5/5 
4 / 4 
6/6 
IgG 
l3asal kcratinoc),tcs 
+ 
5/ 5 
4/4 
(>16 
antibody C terminus a peptidic tag, which can be efficiently 
phosphorylated by casein kinase Il and [1'_32p]ATP to very high 
specifi c activity (Neri et ai, 1996a), and which ca n be detected with 
anti-FLAG antibodies (Hopp el aI, 1988) . The 32P_labeled antibody 
is stable in serum for at least 48 h at 37°C. pDN206 appends CAL 
at the C -tenninal extremity of the recombinant antibody. Several 
ligands, both peptidic and nonpeptidic in nature, bind to CAL with 
nan01110lar affinity or better, and the CAL moiety of the chimeric 
antibody can therefore be used for ta rgeting experiments (Neri et a/, 
1995a). On the basis of the stru cture of the tag used for pDN49, 
pDN284, and pDN206, we wi ll refer to the corresponding scFv 
antibody constru cts as scFv- Cys-myc, scFv-P-FLAG, and scFv-
CAL, respectively. 
We purified our scFv-Cys-myc, scFv-P-FLAG, and scFv-CAL as 
previously described (Materia/s and Met hods; Neri el a/, 1995a, 
1995b, 1996a). Figure 3 shows an sodium dodecyl sulr.,te-polyac-
rylamide gel of purified scFv-P-FLAG, illu strating the degree of 
purity of the antibody preparation after a single purification pas-
sage. Typical yields were 1-10 mg per titer of culture . 
We tested the functionaLi zation of scFv-Cys-myc with a thiol-
specific reagent, iodoacetamidofluorescei n. The resulting fluores-
cently labeled antibody was ana lyzed by sodium dodecyl su lfate-
polyacrylamjde gel electrophoresis (Laemmli, 1970) using the 
fluorescence gel-imager LUANA (Neri ef a/, 1996b) for detection 
(Fig 4a). SimiJarly, scFv(225.28S) could be site- specifi cally bioti-
nylated with iodoacetamido-LC-biotin. ScFv-P-FLAG phosphory-
lation was performed as described (Ned ef a/, 1996a) , using casein 
kinase 2 and [1'-32p]ATP. Figure 4b shows the autoradiogram of a 
sodium dodecyl su lfate-polyacrylamide gel electrophoresis with the 
labeled product and, for control , a 32 P_labeled anti-lysozyme 
antibody. Targeting of scFv-CAL by CAL-binding peptides is 
demonstrated in Fig 4c. ScFv-CAL was incubated with a fluores-
cein-labeled CAL-binding peptide, TAG3, as described (Neri ef at, 
1995a), and the resuJting mixture run on a Pharmacia Homoge-
neous 20 Phast gel with native buffer strips. A strong fluorescent 
band associated with the complex was detected using the lumines-
cence analyser LUANA (Neri et a/, 1996b). 
Bivalent Anti-Melanoma Antibodies Have Higher Func-
tional Affinity than Monovalent Fragmcnts Apparent affin-
ity constants (K~:PP) for COLO-38 cell s for the 225.28S antibody in 
different formats were measured using the SAB method (Mariani et 
at, 1987; Materia/s alld Methods). SAB cu rves were built using the 
four-parameter logistic function; the aBinity constant was evaluated 
tions. Sections a, c, and e were stained with IgG(225.28S) while I), d, andJwere 
stained with scFv(225.28S}. Both reagents react with the keratinocytes of hair 
follicl e (a, b) and with nevus cells (c, cf). Whereas MAb(225.28S) imenseiy 
decorates aU melanoma cells of a m etastatic lesion (c), scFv(225.28S) stains ali 
melanoma cells but wi.th heterogencous intensity (f). a-d) Scale bar, 35 fLl1l; 
e and J), scale IJar, 20 f.LlTI. T he ~ in c marks the ep ide rmis. 
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as the reciprocal of the antibody concentration giving 50')1" satu ra-
ti.on of binding. K::"" for 22S.28S in TgG, F(abb Fab, and scFv-
Cys-myc format are listed in Table I. T he in crease (fi'om 0.5 nM 
to 100 pM levels) of apparent affini ty for bifunctional antibodies 
[IgG, F(abh] is attributable to in creased ,1vidity (Crothers and 
Metzger, 1972). An implication of these resu lts is that bi- or 
m ultivalent recombinant an tibody f0 l"l113ts (Pack ci nl , 1993) should 
be preferable for therapeutic use of the 22S.28S antibody and 
o ptimal binding to melanomas. 
ScFv(225.28S) Retains the Specificity of the Parental IgG 
In addition to binding to the 3n ti-id iotyp ic an tibody MF-1 1 (Fig 2), 
scFv(22S.28S)-Cys-myc was assayed for HM W-MAA binding on 
the m elanoma-de rived COLO-38 cell lin e. A radioimmunoassay 
u sing iodina ted protein LG as detectin g reagent (Kihlberg el nl. 
1992; Vola el nl, 1994) showed that the total radioactivity delivered 
by scFv- Cys-myc and F(ab) 2 to COLO- 38 cells is compal'ablc (data 
not shown). T he immunoreactivity of scFv-Cys-myc is not lost 
upon biotinylation, as is expected beca use of the mild and site-
specific functionali za tion reaction (Fig 1; Mnlerinls nll d MdllOds). 
T h e binding of scFv(22S.28S) -CAL, scFv(225.28S)-P- FLAG, or 
IgG(22S.28S) to COLO-38 melan oma cell s and to HT29 ce lJ s 
(negative control; not shown) was analyzed by con foca l lase r 
microscopy using a human anti-CAL Fab fragment (G riffi ths e/ nl, 
1994; Neri e( nl, 1995a). T he results, shown in Fig 5 for COLO-38 
cells targe ted with scFv(225.28S)-P- FLAG and IgG(22S .28S) , con-
firm th at the specificity of the parental antibody is conserved in the 
recombinant antibody constructs used. 
T h e immunohistochemical reactivity of scFv reagent on n0l111a l 
and transformed tissues is summarized in Table II . T he immuno-
histoch emi cal analysis revea led that both scFv and IgG stained all 
melanoma ce Lis. The stainin g by IgG was in tense and homoge-
neous; the scFv yielded weaker and more variable staining. Exam-
p les of these immuno histochemical findings are shown in Fig 6. 
DJSCUSSION 
The development of murin e MAbs to tumor-associated an tigens 
has resulted in an increasing effort to employ these reagen ts and 
their proteolytic fragments for diagnosis and therapy. At prescnt, no 
gen eral criteria for the selection of antibody-based pharmace uticals 
have been defi ned , even though it is generall y agreed that param-
e ters such as antibody affinity, va lency, specificity, clearance, and 
penetration are of great importance. 
With the advent of recombinant DNA technology and of the 
polym erase chain reaction, it has become possib le to rescue anti-
body genes by po lymerase chain reaction from hybL;domas and to 
express antibody fragments in bacteria (Sken 'a and Pltickthun , 
1988; McCafferty et nl, 1990; Winter and Milstein , 1991). Recom-
binant antibodies ar e typically expressed either as Fab fi.·agments o r 
as scFv fragm ents . Antibodies in scFv configuration pene trate 
tissues m ore efFectively than cOllventional antibodi es and have a 
more rapid clearance (Yokota et nl, 1993). T heir sm all size makes 
them less likely to be immunogenic. 
ScFv production in bacte ria is economical and lends itself w ell to 
industrial production. Even m ore important, the requirem cnts for 
the use of recombinant antibodies in pilot clinical t rials are easily 
met by academic laboratories (Begent ct nl, 1.993). This should 
contribute to overcomin g one of the Inaj or obstacles for the 
development of novel immunopharmaceuticals using hybridoma 
technology: the high cost of production ofa cell bank, which often 
prevents interes ting molecules fro m being investiga ted in the clini c. 
Recombinant antibody modification by protein engineering 
techniques is particularly easy at the gene level. T his ca n provide 
recombinant antibodies with "designe r" effector functions . For 
exampl e, several types of chimeras between recombinant an tibod-
ies and other proteins have been obta ined by sequentially fusin g the 
corresponding genes (for a review, Neri et nl, 1995c) . 
It has recentl y become possible to obtain high-affmity recombi-
nant an tibodies from phage display libraries (Griffiths el nl, 1994; 
Nissin1 el ai, 1994) without immun.ization . Hybridomas producin g 
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well-established antibodies. however, still represent invaluable 
starting materia l for obta ining recombinant antibodies . 
We have reported here the cloning and characterization of the 
anti-me.lanoma 22S.28S antibody in constructs suitable for bacterial 
expression with different effector fl.mctions. We have cloned a 
recombinant scFv fragment antibody with specificity identical to 
tl1at of the pal'enta l IgG(225 .28S) molecule. The recombinant 
antibody can bc produced ill good yield by bacterial fermentation 
and is easy to purify. 
T hree expl-essiOIl vectors , appending three different tags at the C 
terminus of the scFv(225 .28S) , have been developed, which aUow 
t.he cova lent and noncovalent modification of the recombinant 
antibody. By site-specific chemical modification of scFv(22S.28S)-
Cys-myc, the antibody can be armcd with biologically useful 
efFector functions. A mild and stoichiometricall y defined recombi-
na n t antibody conju gation to toxiJ1s , pro-dwg converting enzymes, 
radionuclide chela tOI's, biotin , and other molecules (for a review , 
see Nel; el nl, 1995c) is possible. Direct antibody labeling with 
99n'Tc at the fi'ee thio l group of the cysteine residue (Dean el nl, 
1990; Liberatore CI nl, 1995) may be relevant for immunoscinti-
graphic applications. Furthermore. the same preparation of 
scFv(225 .28S) can be functional ized with different reagents and 
tested for therapeuti c perf0n11ance. 
T he facile, stable , and re latively inexpensive J 2 p labeling of 
scFv-P- FLAG w ith casein kinase II and ["y_32p]ATP opens the way 
to possible rad iotherapcutic applications of scFv(22S.28S). 32p is 
considered an excell ent nuclide because of its physical properties 
and beca use its half-life (14 .3 d) matches the ha.lf-lifc of antibodics 
on tumors (Britton el nl, 1991 ; Howell el nl, 1994). Toward this 
goa l, however, a detailed immulloscin tigraphic investigation of 
scFv(22S.28S) is sti ll req uired . 
CAL- tagged scFv(22S.28S) can be produccd and purified effi-
ciently. Tal'geting with high-aftillity fUllctio nal ized peptidic or 
nonpeptidi c CAL binders (Nel-i 1'1 nl, 1995a; Montigiani el nl, 1996) 
should allow multistep ill1ll1ulloscintigraphic protocols, simil ar to 
what has a.l ready been desct;bed for the biotin-avidin syst.em 
(Paganelli cl nl, 199 1), but with th e possible advantage of the low 
imnlllnogeneicity (VanEldik and Lukas, 1987), and small size of 
CAL. CAL ligands with kinetic association constants ko.1 greate r 
than 10s 1/ sM and kin etic dissociation constant ko tr lower than 
10- s 1 I s are avai lable (Torok and TI·entham. 1994; Neri CI nl, 
1995a; Montigiani I!I nl, 1996). Pre-targeting strategies offer in 
principle th e possibility of experimenta lly varying several parame-
ters such as the amoullt of antibody to be injected, type of targe ting 
molecule, affini ty of pre- targeting binding reaction, and time of 
administration. 
Avidity effects (Crothers and Metzger, 1972) ,Ire likely to play all 
important role in the pcrformance of severa l constructs of binding 
22S.28S antibody to cells. Functional aftlni ty measuremcnts for 
different antibody constructs for 22S.28S have shown that IgG and 
F(ab)2 perform better than Fa b and scFv. For ill I/illO applications, it 
m ay be important to append dimcrization or multirnerization 
domains to scFv(22S .28S) (Pack er nl. '1993; King ct nl. 1994) in 
order to increase antibody residence time o n tWl10rs without 
affecting its residence time in the blood. T hi s would be particularly 
important for therapy with lon g-lived isotopes such as 32p. 
ill conclusion, we h ave deVeloped di.fFerent formats for the 
bacterial expression of recombinant anti-melanoma 22S .28S. These 
functional recombinant protcins should prove valuable as "build-
ing-blocks" for melanoma targeting. 
P.C.N. IIIOS slIpporled h)' PI"I~~ell" F i" o/izzOlo CNR ACRO, by A.lRC, OI,d b)' 11/1' 
110/ioll M illislrl' ~r Pllb/ir Hen/lh . A.l. M. IhOl,ks S ORIN Biolll edirn .Ii,,' ,';'/1/1), 
pn>/lidi"S Ihe IIl Rl\l.-l hoilOle pI"I'/JOrfl liOIl .Ii...,,, Ih" 225.285 I'l'''ridolllo. 
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